International Academy of Cardiology World Congress on Heart Disease

The Congress will provide the opportunity for a comprehensive overview of the latest research developments in Cardiovascular Medicine, primarily in the areas of Molecular and Cellular Cardiology, Genetics of Heart Disease, Cardiac Imaging, Coronary Artery Disease, Peripheral Arterial Disease, Interventional Cardiology, Lipoprotein Disorders, Hypertension, Metabolic Syndrome, Diabetes Mellitus, Cardio-Oncology, Heart Failure, Valvular Heart Disease, Diseases of the Aorta, Cardiac Arrhythmias and Electrophysiology, Implantable Cardiac Pacemakers and Cardioverter-Defibrillators, Sudden Cardi

May 13, 2019 — Boston Scientific announced acute results from the UNTOUCHED study evaluating safety and efficacy of the Emblem subcutaneous implantable defibrillator (S-ICD) system for primary prevention of sudden cardiac death specifically in patients with a left ventricular ejection fraction (LVEF) ≤35 percent. This is the most common population to be indicated for ICD therapy.

May 13, 2019 – Results from a new survey are the first to report a large discrepancy in patient’s knowledge of their cardiac implantable electronic device (CIED). The study reviewed patients’ overall knowledge of data from their devices as well as their perceptions on what is most important. Participants in this study have a strong desire to better understand their device and its data, with more guidance on battery life as the most important aspect for patients.

May 13, 2019 – A first-in-human pilot study of Medtronic's investigational Extravascular Implantable Cardioverter Defibrillator (EV ICD) system showed it can be implanted with no major complications, and can sense, pace and defibrillate the heart. Results from the pilot study were presented during a late-breaking session at Heart Rhythm 2019, the Heart Rhythm Society's 40th Annual Scientific Sessions.

May 13, 2019 — A randomized clinical trial effectively used nerve stimulation through an ear clip to reduce atrial fibrillation (AF) burden and showcases an emerging noninvasive treatment option for patients. The trial is the first to examine the effect of transcutaneous electrical vagus nerve stimulation on suppressing AF.

May 13, 2019 — A digital screening for atrial fibrillation (AFib or AF) successfully monitored more than 60,000 participants from the general population in Belgium using only a smartphone. The results of the late-breaking DIGITAL-AF II study were presented at Heart Rhythm 2019, the Heart Rhythm Society's 40th annual Scientific Sessions.

BioTrace Medical Inc. announced the company’s Tempo Lead has obtained CE Mark certification in Europe for use in cardiac procedures requiring temporary intracardiac pacing.

AliveCor announced its third U.S. Food and Drug Administration (FDA) clearance in three months, making KardiaMobile 6L the world's first available six-lead personal electrocardiogram (ECG) device, according to the company. This clearance gives patients and their physicians an even more detailed view into patients' hearts, including visibility into certain arrhythmias that are leading indicators of cardiovascular disease.

Imricor announced the signing of a commercial agreement with the Haga Hospital in The Hague, Netherlands to outfit a magnetic resonance imaging (MRI) ablation center for treating cardiac arrhythmias.

Subscribe to
© Copyright Wainscot Media. All Rights Reserved.
Subscribe Now